Sign In
7 Mar 2017 13:01
Collagen Solutions Plc
(the "Company")
Director/PDMR Dealing
Collagen Solutions announces that, further to its announcements on 14 February 2017 and 6 March 2017 in connection with the Placing, Open Offer and Debt Financing, the following Directors have acquired Placing Shares pursuant to the Placing at the Placing Price in the following amounts.
Director | Position | Existing Ordinary Shares held | Placing Shares subscribed for at Offer Price | Aggregate price paid for Placing Shares | Number of Ordinary Shares held following Admission |
David Evans | Chairman | 18,874,167 | 16,500,000 | £825,000 | 35,374,167 |
Jamal Rushdy* | Chief Executive Officer | 0 | 1,000,000 | £50,000 | 1,000,000 |
Gillian Black | Chief Financial Officer | 357,143 | 500,000 | £25,000 | 857,143 |
Malcolm Gillies | Non-Executive Director | 1,653,000 | 2,000,000 | £100,000 | 3,653,000 |
*Jamal Rushdy subscribed for such shares pursuant to a separate subscription letter with the Company.
In addition, a call option has been granted to Norgine Ventures by the Company's Chairman, David Evans, in tandem with the warrants issued in relation to the issue of up to £4.0m private bonds, exercisable at an aggregate cost of £1, over a maximum of 20,000,000 of his Ordinary Shares. The call option is only exercisable following any further fundraising having raised over £2,000,000 during the term of the private bonds at a price per share lower than 5.911p, with the number of call options capable of exercise increasing the greater the difference between the price per Ordinary Share at which the further funding is conducted and 5.911p. An exercise of warrants following a fundraising at or above 5.911p would not trigger a right under the call option for David Evans to deliver any shares, while his maximum liability would only arise as a result of a fundraising round as described above and subsequent exercise of the option when the fundraising price was below 1.5785p.
Director | Position | Number of Ordinary Shares held following Admission | Call Options written against shareholding | Number of Ordinary Shares held in the event of a full exercise of Call Option |
David Evans | Chairman | 35,374,167 | 20,000,000 | 15,374,167 |
Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 14 February 2017, which is available to view on the Company's website at www.collagensolutions.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||
a)
| Name
| 1. David Evans 2. Jamal Rushdy 3. Gillian Black 4. Malcolm Gillies
| ||||||||||
2
| Reason for the notification
| |||||||||||
a)
| Position/status
| 1. Chairman 2. Chief Executive Officer 3. Chief Financial Officer 4. Non-Executive Director | ||||||||||
b)
| Initial notification /Amendment
| Initial | ||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||
a)
| Name
| Collagen Solutions plc | ||||||||||
b)
| LEI
| N/A | ||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| New ordinary shares of 1p each
ISIN: GB00B94T6Y14
| ||||||||||
b)
| Nature of the transaction
| Acquisition of new ordinary shares pursuant to placing | ||||||||||
c)
| Price(s) and volume(s)
|
| ||||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
N/A - single transactions
| ||||||||||
e)
| Date of the transaction
| 7 March 2017 | ||||||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |
a)
| Name
| David Evans |
2
| Reason for the notification
| |
a)
| Position/status
| Chairman |
b)
| Initial notification /Amendment
|
Initial Notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
a)
| Name
| David Evans
|
b)
| LEI
| N/A |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
a)
| Description of the financial instrument, type of instrument
Identification code
|
Option to acquire 1p ordinary shares in Collagen Solutions Plc
N/A
|
b)
| Nature of the transaction
| Written Call Option over personal holding. |
c)
| Price(s) and volume(s)
| Price (exercise): £1 (in aggregate) Volume(s): up to 20,000,000
|
d)
| Aggregated information
- Aggregated volume
- Price
|
N/A
N/A
|
e)
| Date of the transaction
| 6 March 2017 |
f)
| Place of the transaction
| Outside a trading venue |
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.
Enquiries:
Collagen Solutions Plc | Contact via Walbrook | ||
Jamal Rushdy, Chief Executive Officer |
| ||
Gill Black, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated Adviser and Broker) Stephen Keys Steve Cox Callum Davidson | Tel: 0207 397 8900
| ||
|
| ||
Walbrook PR | Tel: 020 7933 8780 or collagen@walbrookpr.com | ||
Mike Wort | Mob: 07900 608 002 | ||
Anna Dunphy | Mob: 07876 741 001 | ||
Follow the stocks
